PharmX Technologies (ASX:PHX) 3-Year Revenue Growth Rate : -26.30% (As of Dec. 2023)

View and export this data going back to 1973. Start your Free Trial

What is PharmX Technologies 3-Year Revenue Growth Rate?

PharmX Technologies's Revenue per Share for the six months ended in Dec. 2023 was A$0.01.

During the past 12 months, PharmX Technologies's average Revenue per Share Growth Rate was -75.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -26.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -22.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was -16.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of PharmX Technologies was 15.00% per year. The lowest was -35.00% per year. And the median was -15.30% per year.

Competitive Comparison of PharmX Technologies's 3-Year Revenue Growth Rate

For the Health Information Services subindustry, PharmX Technologies's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmX Technologies's 3-Year Revenue Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's 3-Year Revenue Growth Rate falls into.

PharmX Technologies 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

PharmX Technologies (ASX:PHX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

PharmX Technologies 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of PharmX Technologies's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmX Technologies (ASX:PHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PharmX Technologies Ltd (ASX:PHX) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Castlereagh Street, Level 11, Sydney, NSW, AUS, 2000

Website

https://www.corumgroup.com.au

PharmX Technologies Ltd Formerly Corum Group Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business. the company discontinued the e-commerce business in 2022.